Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of “Moderate Buy” by Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $105.80.

IRON has been the subject of a number of recent research reports. Morgan Stanley boosted their price target on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Wedbush restated an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Wells Fargo & Company raised their target price on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Finally, Truist Financial reduced their target price on Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 27th.

Insiders Place Their Bets

In other Disc Medicine news, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total value of $433,234.68. Following the completion of the sale, the chief financial officer owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. This represents a 8.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,758,677.56. The trade was a 25.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 31,000 shares of company stock worth $2,129,023. Insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP bought a new stake in Disc Medicine in the first quarter valued at approximately $207,000. Bank of America Corp DE lifted its holdings in shares of Disc Medicine by 22.6% during the 1st quarter. Bank of America Corp DE now owns 166,775 shares of the company’s stock valued at $10,664,000 after purchasing an additional 30,789 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Disc Medicine by 47.8% during the 1st quarter. California State Teachers Retirement System now owns 34,382 shares of the company’s stock valued at $2,198,000 after purchasing an additional 11,126 shares in the last quarter. SummitTX Capital L.P. bought a new position in shares of Disc Medicine during the 1st quarter valued at about $884,000. Finally, Octagon Capital Advisors LP bought a new position in shares of Disc Medicine during the 1st quarter valued at about $17,264,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Performance

IRON opened at $70.79 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -10.69 and a beta of 0.93. The firm has a 50 day simple moving average of $68.61 and a 200 day simple moving average of $71.77. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, sell-side analysts anticipate that Disc Medicine will post -6.74 earnings per share for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.